From the observation DAC: Romidepsin revisited

Blood

Volumn 118, Issue 24, 2011, Pages 6231-6232

  Knop, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHAPERONE; DEXAMETHASONE; DNA; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; LYSINE; REACTIVE OXYGEN METABOLITE; RNA POLYMERASE; ROMIDEPSIN; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOTRANSPLANTATION; BONE MARROW; CHROMATIN; DISEASE COURSE; DNA BINDING; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FATIGUE; HISTONE ACETYLATION; HUMAN; HYPONATREMIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NEUTROPENIA; NONHODGKIN LYMPHOMA; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK; T CELL NONHODGKIN LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 83455220312     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-381046     Document Type: Note

References (9)

1. Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;118(24):6274-6283.
2. Stewart AK. Novel therapies for relapsed myeloma. Hematology Am Soc Hematol Educ Program. 2009;578-586.
3. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117(2):336-342.
4. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-5552. (Pubitemid 47255934)
5. Robey RW, Chakraborty AR, Basseville A, et al. Histone deacetylase inhibitors: emerging mechanisms of resistance [published online ahead of print September 7, 2011]. Mol Pharm. doi:10.1021/mp200329f.
6. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417.
7. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol. 2010;89(2):185-190.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
9. Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116(3):406-417.